[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362324-105":59,"doc-detail-362324-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-immunotherapy-for-bladder-cancer-and-clinical-practice-of-next-generation-sequencing-review","Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing - Review","","Advances in immunotherapy for bladder cancer reviews how treatment has evolved from decades of platinum-based chemotherapy to precision approaches enabled by next-generation sequencing. The review links high mutation burden and microsatellite instability–high/deficient mismatch repair to the clinical use of immune checkpoint inhibitors, discusses molecular targets for targeted agents, and summarizes molecular features and subtypes that guide future therapy. It also outlines direction for ongoing development of new drugs and treatment strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-immunotherapy-for-bladder-cancer-and-clinical-practice-of-next-generation-sequencing-review/362324/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-immunotherapy-for-bladder-cancer-and-clinical-practice-of-next-generation-sequencing-review/362324.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What major treatment shift is discussed for metastatic and locally advanced bladder cancer?","Question",{"text":112,"@type":113},"The review explains that standard therapy has long relied on platinum-based chemotherapy, but next-generation sequencing has supported faster characterization of bladder cancer genomes and enabled immunotherapy and targeted approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biomarkers are highlighted for immune checkpoint inhibitor use?",{"text":117,"@type":113},"It emphasizes indications including high mutation burden and microsatellite instability–high/deficient mismatch repair, where immune checkpoint inhibitors have shown good response.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review describe bladder cancer classification and its clinical implications?",{"text":121,"@type":113},"Bladder cancer is divided into nonmuscle invasive and muscle-invasive disease based on invasion depth, with nonmuscle invasive cases forming a large proportion while high-risk NMIBC can progress to muscle-invasive disease.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362324,1792028771,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","TYPE Review  \nPUBLISHED 21 January 2026  \nDOI 10.3389/fimmu.2025.1684597  \nOPEN ACCESS  \nEDITED BY  \nGiandomenico Roviello, University of Firenze, Italy  \nREVIEWED BY  \nLei Yin,  \nShanghai Jiaotong University School of Medicine, China  \nKhaled Alqarni,  \nUniversity of Jeddah, Saudi Arabia  \n*CORRESPONDENCE  \nJi Zheng  \n [Jizheng@tmmu.edu.cn](Jizheng@tmmu.edu.cn)[ ](Jizheng@tmmu.edu.cn)Wei Chen  \n [doctorcw@tmmu.edu.cn](doctorcw@tmmu.edu.cn)  \nRECEIVED 12 August 2025  \nREVISED 18 December 2025  \nACCEPTED 31 December 2025  \nPUBLISHED 21 January 2026  \nCITATION  \nNing W, Chang P, Zheng J and Chen W (2026) Advances in immunotherapy for bladder cancer and clinical practice of nextgeneration sequencing.  \nFront. Immunol. 16:1684597 .  \ndoi: 10.3389/fimmu.2025.1684597  \nCOPYRIGHT  \n© 2026 Ning, Chang, Zheng and Chen. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAdvances in immunotherapy for bladder cancer and clinical practice of nextgeneration sequencing  \nWei Ning 1, Pengkang Chang 1, Ji Zheng 1* and Wei Chen 1,2*  \n1 Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China, 2 Department of Urology of Jiangbei Campus, The First Afﬁliated Hospital of Army Medical University (The 958th Hospital of Chinese People’s Liberation Army), Chongqing, China  \nBladder cancer kills nearly 170,000 people worldwide each year. Over the past 4 decades, the systematic treatment of metastatic and locally advanced bladder cancer has mainly consisted of platinum-based chemotherapy. In the last 10 years, the development of next-generation sequencing have led to rapid characterization of whole-genome sequencing of bladder cancer, which gives us a better understanding of the pathogenesis of bladder cancer. Based on indications of high mutation burden, and microsatellite instability-high/deﬁcient mismatch repair, immune checkpoint inhibitors have been studied in metastatic and locally advanced bladder cancer as well as bladder-sparing, and shows a good response in these speciﬁc indications. Besides, clinically signiﬁcant expressed molecular targets are used to develop cancer targeted drugs, such as ﬁbroblast growth factor receptor inhibitors and antibody-drug coupling agents. The exploration of molecular characteristics and subtypes of bladder cancer and the development of new drugs and treatment strategy have also stimulated more clinical studies of bladder cancer. Here, we review advances in the treatment of bladder cancer and clinical practice of next-generation sequencing, highlight important advances in immunotherapy for bladder cancer, preliminarily summarize molecular features of bladder cancer for clinical practice, and came up with direction for future treatment development.  \nKEYWORDS  \nantibody-drug coupling agent, bladder cancer, ﬁbroblast growth factor receptor inhibitors, immune checkpoint inhibitors, next-generation sequencing, trimodality therapy  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \n1.1 Epidemiological investigation  \nBladder cancer (BC) is a common malignancy worldwide, with approximately 500,000 new cases and more than 170,000 deaths annually (1) . It is one of the three most common tumors of the urinary and reproductive system and is the ninth most common neoplasm and the thirteenth leading cause of cancer death in the world. Men are 3–4 times more likely to develop BC than women (2, 3) . The aging of the global population and changes in lifestyle and environment are also affecting incidence and mortality of ","cbCaiqS2UK858cvc","https://ap.wps.com/l/cbCaiqS2UK858cvc","pdf",660772,12,"English","# Introduction\n## Epidemiological investigation\n## Histopathological classification\n## Traditional treatment model","[{\"question\":\"What major treatment shift is discussed for metastatic and locally advanced bladder cancer?\",\"answer\":\"The review explains that standard therapy has long relied on platinum-based chemotherapy, but next-generation sequencing has supported faster characterization of bladder cancer genomes and enabled immunotherapy and targeted approaches.\"},{\"question\":\"Which biomarkers are highlighted for immune checkpoint inhibitor use?\",\"answer\":\"It emphasizes indications including high mutation burden and microsatellite instability–high/deficient mismatch repair, where immune checkpoint inhibitors have shown good response.\"},{\"question\":\"How does the review describe bladder cancer classification and its clinical implications?\",\"answer\":\"Bladder cancer is divided into nonmuscle invasive and muscle-invasive disease based on invasion depth, with nonmuscle invasive cases forming a large proportion while high-risk NMIBC can progress to muscle-invasive disease.\"}]","Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing - Review | PDF",1790147105,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72c5c49b87ba457b131e9b2bb2e22063.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0949b7f5dbd846f6a0e30b4955c4991.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2505d8c4121ab92236a25b574dfe91ab.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b368d1c90efb284bd2b5f3a4bf3e2533.webp",980,1385]